207 related articles for article (PubMed ID: 11745508)
1. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications.
Han BH; Wallner KE
Int J Cancer; 2001 Dec; 96(6):372-8. PubMed ID: 11745508
[TBL] [Abstract][Full Text] [Related]
2. Rectal dosimetric analysis following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Walbert HL; Blatt HJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1021-7. PubMed ID: 10192350
[TBL] [Abstract][Full Text] [Related]
3. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.
Snyder KM; Stock RG; Hong SM; Lo YC; Stone NN
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):335-41. PubMed ID: 11380219
[TBL] [Abstract][Full Text] [Related]
4. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
[TBL] [Abstract][Full Text] [Related]
5. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding.
Mueller A; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1047-52. PubMed ID: 15234038
[TBL] [Abstract][Full Text] [Related]
6. Probability of late rectal morbidity in 125I prostate brachytherapy.
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
[TBL] [Abstract][Full Text] [Related]
7. Rectal function following permanent prostate brachytherapy.
Merrick GS; Butler WM
W V Med J; 2004; 100(1):18-20. PubMed ID: 15119492
[TBL] [Abstract][Full Text] [Related]
8. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Cleavinger S
Brachytherapy; 2003; 2(3):147-57. PubMed ID: 15062137
[TBL] [Abstract][Full Text] [Related]
9. Difference in the rate of rectal complications following prostate brachytherapy based on the prostate-rectum distance and the prostate longitudinal length among early prostate cancer patients.
Kang MH; Yu YD; Shin HS; Oh JJ; Park DS
Korean J Urol; 2015 Sep; 56(9):637-43. PubMed ID: 26366276
[TBL] [Abstract][Full Text] [Related]
10. Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.
Kishan AU; Kupelian PA
Brachytherapy; 2015; 14(2):148-59. PubMed ID: 25516492
[TBL] [Abstract][Full Text] [Related]
11. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
Cesaretti JA; Stock RG; Atencio DP; Peters SA; Peters CA; Burri RJ; Stone NN; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1410-6. PubMed ID: 17490827
[TBL] [Abstract][Full Text] [Related]
12. Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer.
Ishiyama H; Kitano M; Satoh T; Niibe Y; Uemae M; Fujita T; Baba S; Hayakawa K
Radiother Oncol; 2006 Feb; 78(2):194-8. PubMed ID: 16414135
[TBL] [Abstract][Full Text] [Related]
13. Argon plasma coagulation for rectal bleeding after prostate brachytherapy.
Smith S; Wallner K; Dominitz JA; Han B; True L; Sutlief S; Billingsley K
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):636-42. PubMed ID: 11597803
[TBL] [Abstract][Full Text] [Related]
14. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
[TBL] [Abstract][Full Text] [Related]
15. [Normal tissue tolerance to external beam radiation therapy: rectum].
Blanchard P; Chapet O
Cancer Radiother; 2010 Jul; 14(4-5):354-8. PubMed ID: 20570201
[TBL] [Abstract][Full Text] [Related]
16. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
17. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
19. The effect of constipation on rectal dosimetry following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Dorsey JT
Med Dosim; 2000; 25(4):237-41. PubMed ID: 11150696
[TBL] [Abstract][Full Text] [Related]
20. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors.
Shah JN; Ennis RD
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):817-24. PubMed ID: 16297567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
